Royalty Pharma ($RPRX) Insider Trading & Smart Money Activity
Royalty Pharma plc ($RPRX) has 6 insider trades, 2 13F position changes and 1 analyst rating on file. In the last 12 months on the open market, no insider bought and 4 insiders sold ($14.99M), net -$14.99M.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 4
- Net insider $ (12 mo)
- -$14.99M
- Congress trades (12 mo)
- 0
- 13F moves on file
- 2
- Analyst ratings on file
- 1
RPRX insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 2 · $8.66M | 0 / 0 | 0 / 2 |
| Q3 2026 | 0 | 2 · $6.09M | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 1 · $235.59K | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All RPRX insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Analyst | Morgan Stanley | Reiterates to Overweight | PT $67 | +3.9% | — | ||||||
| Insider | Urist MarshallEVP, Research & Investments | Sell (Open-market sale) 10b5-1 | 4.13K sh | $235.59K | +2.0% | — | |||||
| Insider | Urist MarshallEVP, Research & Investments | Sell (Open-market sale) 10b5-1 | 4.13K sh | $238.81K | -2.9% | — | |||||
| Insider | Hite ChristopherEVP & Chairman, Partnering | Sell (Open-market sale) 10b5-1 | 100K sh | $5.85M | -0.5% | — | |||||
| Insider | Bonnie Bassler | Buy (Grant or award) | 689 sh | $37.48K | +3.1% | +5.3% | Read | ||||
| Insider | Marshall UristEVP, Research & Investments | Sell (Open-market sale) 10b5-1 | 9.10K sh | $502.03K | +2.8% | +8.4% | — | ||||
| Insider | Christopher HiteEVP & Chairman, Partnering | Sell (Open-market sale) 10b5-1 | 150K sh | $8.16M | +1.3% | +6.6% | — | ||||
| 13F | Baillie Gifford | Reduced | -853.09K sh | $891.44M | +4.5% | +8.5% | — | ||||
| 13F | Baillie Gifford | Reduced | -853.09K sh | $922.33M | +4.5% | +8.5% | — |
1W / 1M / 6M = how RPRX moved from the trade or filing date.
Insider trading in RPRX: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Urist Marshall | EVP, Research & Investments | 2 | -$474.41K | Oct 5, 2026 | |
| Hite Christopher | EVP & Chairman, Partnering | 1 | -$5.85M | Sep 22, 2026 | |
| Bonnie Bassler | 1 | — | Jun 30, 2026 | ||
| Marshall Urist | EVP, Research & Investments | 1 | -$502.03K | Jun 24, 2026 | |
| Christopher Hite | EVP & Chairman, Partnering | 1 | -$8.16M | Jun 23, 2026 |
Institutions moving RPRX (13F)
Analyst ratings on RPRX
| Date | Firm | Action | Rating | Price target | 1W | 1M | 6M | Story |
|---|---|---|---|---|---|---|---|---|
| Morgan Stanley | Reiterates | Overweight | $65 → $67 | +3.9% | — |
Frequently asked questions
Are RPRX insiders buying or selling?
Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 4 insiders made 5 open-market sales worth $14.99M, a net -$14.99M.
What is the latest insider trade in RPRX?
Urist Marshall, EVP, Research & Investments filed a sell (open-market sale) of 4.13K sh worth $235.59K on Oct 5, 2026.
Which institutions changed their RPRX positions?
Recent 13F filers moving the stock include Baillie Gifford.
Other biotechnology stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.